All In Biotech

Investigational drug · Phase 2

GT101

Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Recurrent or Metastatic Cervical Cancer.

Phase 2

Last checked: Nov 19, 2026Latest source record: Nov 12, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations

Highest phase

Phase 2

Industry-sponsored trials

Phase 2 and 3 trials

1

1 still active

All registered trials

3

Any phase or sponsor naming "GT101"

First trial start

2024

Apr 2, 2024

Sponsors

Lead sponsors of its Phase 2 and 3 trials.

All registered trials by phase

Every ClinicalTrials.gov drug study naming "GT101", any sponsor or status.

Conditions studied

As listed on its trial records.

  • Recurrent or Metastatic Cervical Cancer

Approved drugs for the same conditions: Cervical cancer · Oncology

Largest trials

Live from ClinicalTrials.gov: studies naming "GT101" as an intervention, largest first.

All trials

Newest research

PubMed records naming it or its code names, newest first.

All 3 on PubMed

Also in development for Recurrent or Metastatic Cervical Cancer

  • SHR-A1811Trastuzumab RezetecanPhase 327 trials

    Jiangsu HengRui Medicine Co., Ltd. · Advanced Colorectal Cancer, Recurrent or Metastatic Cervical Cancer, Ovarian Cancer

  • CamrelizumabSHR-1210, CAMPhase 39 trials

    Jiangsu HengRui Medicine Co., Ltd. · HCC, Non-squamous Non-small Cell Lung Cancer, Hepatocellular Carcinoma

  • GEMPhase 35 trials

    Shenzhen Majory Biotechnology Co., Ltd. · Pancreatic Ductal Adenocarcinoma (PDAC), Pancreatic Cancer, Recurrent or Metastatic Cervical Cancer

  • JSKN033Phase 34 trials

    Jiangsu Alphamab Biopharmaceuticals Co., Ltd · Cervical Cancer, Recurrent or Metastatic Cervical Cancer, Advanced Malignant Tumors

  • AdebelimabPhase 22 trials

    Shanghai Hengrui Pharmaceutical Co., Ltd. · Advanced Solid Tumors, Recurrent or Metastatic Cervical Cancer

  • FamitinibSHR-1020Phase 21 trial

    Jiangsu HengRui Medicine Co., Ltd. · Recurrent or Metastatic Cervical Cancer

Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.